M&A

A deal happens when a buyer believes the combined company will be worth more than the two companies were worth apart, so that the buyer comes out ahead even after paying for the target. Most of that extra value comes from synergies, which split into two types that interviewers expect a candidate to name specifically. Cost synergies come from cutting overlapping functions, a duplicate headquarters, back office, or sales force, and are relatively easy to identify and quantify. Revenue synergies come from selling more across the combined customer base, cross-selling each company's products to the other's customers, and are considerably harder to pin down and more speculative in practice. A buyer that can fold the target into operations it already runs can capture both kinds, which is exactly why the target is worth more in that buyer's hands than it is standing alone.

Deal motivations split into financial rationale, reasons a buyer can put a specific number behind, and strategic rationale, reasons that matter just as much but are harder to price precisely. Financial rationale covers consolidation and economies of scale (a larger combined company gets better supplier terms and spreads fixed costs over more volume), geographic expansion (buying an established player in a new region is faster than entering it from scratch), market share (buying a competitor adds share immediately in a slow-growing market), and an undervalued target (the buyer sees a chance to acquire a good business cheaply after its price has fallen). Strategic rationale covers acquiring technology or intellectual property the buyer doesn't have and would take years to build, a defensive acquisition of a fast-growing competitor before it can disrupt the buyer's core business, an acqui-hire done mainly to bring on a target's team, and product expansion into an adjacent line faster than organic growth would allow.

In practice the two categories are linked rather than separate: management typically decides to pursue a deal for an underlying strategic reason first, then builds the financial case to justify it to the board and to shareholders, so a complete rationale answer names both the underlying driver and the supporting numbers.

Acquirers come in two types, and the difference shapes how much each can justify paying for the same target. A strategic buyer is an operating company in the same or an adjacent business, and it can fold the target into existing operations and capture synergies, so it values the target's earning power above what the target produces standalone. A financial buyer, typically a private equity firm, holds the target as a standalone investment bounded by a required return over a fixed holding period, so it values the target closer to its own unassisted cash flows. That difference in what each buyer type can capture is exactly why a strategic buyer can usually justify a higher price than a financial buyer for the identical business.

This distinction also connects directly to why a deal's earnings-per-share impact matters so much at announcement. A deal that raises the acquirer's EPS in the near term is accretive and a deal that lowers it is dilutive, and dilutive deals tend to pull an acquirer's share price down at announcement even when the long-term strategic logic is sound, which is part of why the accretion/dilution math gets so much attention separately from the underlying rationale for doing the deal at all.

Weighing a deal against building the same capability internally comes down to time and risk: buying brings a proven product, team, and revenue immediately, while building takes years with no guarantee it works, which is also the logic behind an acqui-hire (buying a small company mainly to bring on its team) and a defensive acquisition (buying a fast-growing competitor before it can disrupt the buyer's own core business). When a deal is announced, the two stocks typically move in opposite directions: the target's shares jump toward the offer price, since it's being paid a premium, and the small remaining gap to the offer, the deal spread, reflects the market's read on the odds the deal actually closes, while the acquirer's shares often dip, since the market is pricing the premium paid, integration risk, and any EPS dilution from how the deal is financed.

Most deals that fail to create value do so not because the strategic logic was wrong but because the buyer paid for synergies that never fully showed up: the premium is paid up front while the synergies, especially revenue synergies, arrive over years if at all, and integration costs routinely run higher than planned.

A typical sell-side M&A process moves through defined phases: preparation (building marketing materials, identifying buyers), then a first round where a teaser (a brief, anonymous overview) goes to a broad buyer list and interested parties sign an NDA to receive a confidential information memorandum (CIM) and submit non-binding indications of interest; a smaller group of buyers advances to a second round with deeper diligence access (management presentations, data room access) and submits binding final bids; the seller negotiates and selects a winner, and the parties sign a definitive purchase agreement, followed by a period between signing and closing to satisfy remaining conditions (regulatory approval, financing) before the deal actually closes.

The entire process, from initial preparation to closing, typically runs several months to a year depending on deal complexity, regulatory scrutiny, and how competitive the process is.

A broad auction contacts a large number of potential buyers to maximize competitive tension and price, at the cost of more information leakage risk and a heavier process burden on the seller and target management. A narrow or negotiated sale approaches only one or a small handful of buyers, trading away some price competition for speed, confidentiality, and certainty of execution, often the right choice when a specific strategic buyer is clearly the best fit, or when confidentiality concerns (competitive sensitivity, employee morale) outweigh the value of a wider auction.

The choice of process type is itself a piece of advice a banker gives a client early on, based on the specific asset, the likely buyer universe, and the seller's priorities, it isn't a fixed default.

On a buy-side mandate the bank represents the company that wants to acquire, not the one being sold, so the work runs in reverse: define a target profile (industry, size, financial characteristics, strategic fit) with the client, build and evaluate a list of possible targets, quietly approach the most promising ones to gauge interest, then run diligence and valuation and advise on price once a target engages. There's no teaser or CIM and no fixed bidding rounds, since the bank isn't marketing anything to a wide buyer pool, which makes a buy-side process considerably less structured than a sell-side auction. Once a target does engage, the later stages converge with a sell-side deal, both sides run diligence, exchange information, and negotiate a definitive agreement, and the real difference throughout is simply which side of the table the bank sits on.

On either kind of mandate, analysts do most of the process's operational work: building and updating the pitchbook, teaser, CIM, valuation model, and data room. Associates and VPs review that work, manage buyer questions, and keep the process on schedule, while senior bankers run the client relationship, lead negotiation, and advise the board on price and terms.

An indication of interest (IOI) is the first-round bid: non-binding, with a rough price range, used to narrow the buyer list to serious candidates. A letter of intent (LOI) comes later, after real diligence, still mostly non-binding but with a specific price, structure, and key terms, and it's the bid the seller actually picks its preferred buyer from, the progression from IOI to LOI is how an auction funnel narrows. Signing the definitive agreement sets the deal's terms but is not the same as closing: the two sides still have to clear conditions (regulatory and antitrust approval, financing, sometimes a shareholder vote) that can take anywhere from a few weeks to several months, and contracts commonly include a break-up fee the seller owes the buyer if it walks away for a higher offer, compensating the original buyer for the time and cost already sunk into the deal.

Separately, 'merger' and 'acquisition' describe the same legal mechanics but different framing: an acquisition is a clearly larger buyer purchasing a smaller target that gets folded in, while a merger combines two companies of comparable size, and many deals labeled 'mergers of equals' are, in substance, one company acquiring the other, the label often reflects how the parties want the deal perceived by employees and shareholders more than a strict legal distinction. A deal can still fail at any point before close: diligence turning up a problem, financing falling through, an antitrust block, a shareholder or board rejection, or market conditions shifting between signing and closing.

In an all-cash deal, the acquirer pays target shareholders in cash, funded from the balance sheet, new debt, or a combination. Target shareholders get certainty of value (a fixed dollar amount per share) and a taxable event immediately upon closing. For the acquirer, cash avoids diluting existing shareholders but increases leverage (if debt-funded) or depletes balance sheet flexibility (if funded from cash on hand), and it means the acquirer bears 100% of the risk (and upside) of the combined business going forward, since target shareholders have fully exited.

Cash deals are generally preferred by acquirers with strong balance sheets or cheap access to debt financing, and by targets whose shareholders want a clean, certain exit rather than continued exposure to the combined company's stock.

A deal can also be funded with newly raised debt rather than cash off the balance sheet, and it shares cash's core advantage, no new shares, no dilution, while carrying a different cost. Debt is more expensive than spending idle cash, since the interest paid on new borrowing runs well above the interest income cash would otherwise earn, but it's still cheaper than issuing stock, because lenders take less risk than equity holders (they get paid first if the deal goes bad, so they accept a lower return) and interest expense is tax-deductible, which lowers its effective cost further. Debt capacity is not unlimited: lenders watch debt-to-EBITDA and interest-coverage ratios closely, and the rate an acquirer pays climbs as it takes on more leverage relative to its earnings, so debt financing is capped by the acquirer's credit profile the same way cash financing is capped by its cash balance.

In an all-stock deal, target shareholders receive shares of the acquirer instead of cash, becoming shareholders in the combined company, they don't fully exit, and instead share in the upside (and risk) of the merger going forward. Stock deals are typically structured as a fixed exchange ratio (a set number of acquirer shares per target share) or, less commonly, a fixed value (the exchange ratio floats to deliver a set dollar value, protecting target shareholders from acquirer share-price swings between announcement and closing).

For the acquirer, stock avoids taking on new debt and preserves balance sheet capacity, but dilutes existing shareholders' ownership. Stock deals can also often be structured to defer capital gains tax for target shareholders (since they haven't actually 'cashed out'), which is a meaningful consideration in deal negotiations.

Many deals use a mix of cash, debt, and stock, letting the acquirer balance the tradeoffs of each, limiting new leverage while still avoiding excessive dilution, and giving target shareholders some certainty (the cash portion) alongside some continued upside (the stock portion). Because cash is the cheapest source, debt sits in the middle, and stock is the most expensive, acquirers generally draw on them in that order, cash first, then debt, then stock, turning to a mix mainly when a target is too large to fund with cash and debt capacity alone. The final mix in a real negotiation also reflects how confident the acquirer is that its own stock is fairly valued (an acquirer that believes its stock is undervalued strongly prefers cash or debt, to avoid 'overpaying' in effectively discounted currency) and what target shareholders are willing to accept.

The consideration mix also determines who bears the price risk between signing and closing: a fixed exchange ratio in a stock deal puts that risk on the target's shareholders, a floating ratio shifts it to the acquirer's, and a collar caps the exposure on both sides if the stock swings sharply. It also directly determines whether the deal is accretive or dilutive to the acquirer's EPS, and whether it's a taxable or tax-deferred event for target shareholders, which is why it's negotiated as carefully as the headline price itself, not treated as an afterthought. The gap between the target's post-announcement trading price and the offer price, the deal spread, reflects the market's own read on how likely the deal is to close, and merger-arbitrage funds trade specifically on that gap.

Accretion/dilution tests whether an acquisition raises or lowers the acquirer's earnings per share, always diluted EPS, since merger models run on the share count that includes what options and convertibles would add once the deal closes. The build combines the acquirer's and target's standalone net income, adds any synergies net of tax, subtracts new interest expense (if debt funds the deal) or forgone interest income (if cash does), and subtracts the after-tax amortization of any new intangibles the deal's purchase accounting creates, to arrive at pro forma combined net income; dividing that by the pro forma diluted share count (existing acquirer shares plus any new shares issued) gives pro forma EPS, compared against the acquirer's standalone EPS to call the deal accretive or dilutive.

For a simple all-stock deal there's a fast shortcut built on earnings yield, the inverse of a P/E: compare the acquirer's P/E to the target's purchase P/E, the target's standalone P/E grossed up by the acquisition premium (a 15x target bought at a 30% premium has a 19.5x purchase P/E). If the acquirer's P/E sits above the target's purchase P/E, the acquirer is buying a higher earnings yield with relatively cheap stock, and the deal is accretive; if the acquirer's P/E sits below it, the deal is dilutive; equal multiples produce a neutral result. This shortcut is a fast sanity check, not a substitute for the full build, since it ignores synergies and purchase-accounting amortization.

The financing method changes the outcome directly. An all-cash deal funded from the balance sheet avoids issuing new shares (no dilution from share count) but reduces interest income or adds interest expense if debt-funded, meaning the deal's accretion/dilution outcome depends heavily on whether the target's earnings yield (net income divided by purchase price) exceeds the after-tax cost of the cash or debt used to fund it. An all-stock deal avoids new interest costs but dilutes existing shareholders' ownership by issuing new shares, meaning the outcome depends heavily on the relative P/E multiples of acquirer and target, as in the shortcut above.

The same cost-versus-yield logic sets a breakeven premium: in an all-stock deal, the premium that pushes the target's purchase P/E up to equal the acquirer's own P/E is the point where the deal flips from accretive to dilutive, calculated as the acquirer's P/E divided by the target's standalone P/E, minus one. A 20x acquirer buying a 15x target turns dilutive above roughly a 33% premium, all else equal, which is exactly why bankers run the analysis under multiple consideration scenarios and premium levels before recommending a structure to a client.

Public market investors and analysts scrutinize a deal's near-term accretion/dilution closely, and an acquirer's stock price often reacts to it directly on deal announcement, even though accretion/dilution, by itself, says nothing definitive about whether a deal creates real long-term value (a dilutive deal can still be strategically excellent if it builds durable competitive advantage; an accretive deal can still destroy value if the acquirer overpays or fails to integrate well).

Boards and management teams are aware of this market reaction and often manage deal structure specifically to avoid near-term dilution, or to be able to credibly explain why a dilutive deal is still the right long-term decision, which is why this analysis, despite its real limitations as a measure of value creation, remains one of the first things a banker builds when advising on a potential acquisition.

Cost synergies come from eliminating duplicate expenses after a merger: redundant corporate functions (finance, HR, legal), overlapping facilities or real estate, combined procurement giving the merged company more purchasing leverage with suppliers, and consolidated technology systems. Cost synergies are generally viewed as the more reliable, more quickly realized category, they're within management's direct control to execute and don't depend on customer or market behavior, which is why they typically carry more weight in a deal's investment case and in the multiple an acquirer is willing to pay.

Even so, cost synergies come with real execution cost and risk: severance for eliminated roles, system integration costs, and the organizational disruption of combining two workforces, all of which should be netted against the projected savings in a credible synergy case.

Revenue synergies come from growth opportunities the combined company can pursue that neither company could alone: cross-selling each company's products into the other's customer base, geographic expansion using the combined distribution footprint, or bundling complementary products into a stronger combined offering. Revenue synergies are viewed as far less reliable than cost synergies, because they depend on customer behavior and competitive response that management doesn't fully control, and they typically take longer to materialize, if they materialize at all.

Because of that unreliability, sophisticated buyers, boards, and analysts discount revenue synergy claims heavily, or exclude them from the price they're willing to pay entirely, treating them as a possible upside rather than a value being paid for upfront.

Neither synergy type shows up the day a deal closes. Integration takes time, so realized savings build toward the full run-rate, the annual benefit once every planned action is complete, on a phased schedule over roughly two to three years (for example, 40% of the run-rate in year one, 70% in year two, the full amount from year three on), and modeling the entire run-rate as if it hits in year one overstates the near-term EPS benefit. Both synergy types also carry a one-time cost to achieve (severance for eliminated roles, system integration, facility consolidation) that has to be netted against the projected savings in any honest estimate.

Synergies are also how the maximum defensible price gets set: the most a buyer can justify paying is the target's standalone value plus the net, risk-adjusted, after-tax value of the synergies (capitalized as a perpetuity), and a disciplined buyer keeps its premium below that ceiling rather than paying away the entire synergy benefit, so its own shareholders keep some of the value created. First-year EPS dilution from a deal is not, by itself, a reason to walk away: if the full synergy stream is worth more than the premium once it ramps, the deal can still create value even though near-term EPS dips.

Purchase price allocation is the accounting process of assigning the total price paid in an acquisition across the fair value of the target's identifiable assets and liabilities, with any remaining premium recorded as goodwill. The process: revalue the target's tangible assets (PP&E, inventory) to fair value if it differs from book value; identify and value intangible assets not previously on the target's own balance sheet (customer relationships, developed technology, trade names, often valued using specialized techniques like the relief-from-royalty or multi-period excess earnings methods); assume the target's liabilities at fair value; and the excess of purchase price over this net fair value becomes goodwill.

This process happens in the months following a deal's close (sometimes with a provisional allocation booked at close, finalized within a year), and it directly determines the acquirer's future D&A expense and, ultimately, reported earnings from the acquired business.

When acquired assets are written up ('stepped up') to fair value for book purposes but retain their original, lower tax basis, the difference creates a new deferred tax liability, since the company will eventually owe more tax than its book depreciation/amortization schedule alone would suggest (it can't depreciate the stepped-up value for tax purposes the way it can for books). This new DTL is itself part of what completes the purchase price allocation puzzle, alongside the identifiable intangibles and goodwill.

This is a frequent, precise interview follow-up to a basic PPA question: being able to explain not just that intangibles get stepped up, but that the step-up creates a tax/book basis difference and therefore a new deferred tax liability, is a meaningful signal of depth.

The specific intangibles identified and their assigned useful lives directly determine the new amortization expense the combined company will report going forward, a key input into the accretion/dilution analysis, since higher amortization from a large step-up directly reduces pro forma combined net income and EPS. Because a full, formal PPA typically isn't available until after a deal is well underway or closed, merger models built at the time of a proposed transaction usually rely on simplified assumptions (an estimated percentage of purchase price allocated to intangibles, an assumed useful life) rather than a precise allocation.

This is also why deal announcements often include a rough, illustrative PPA in the transaction materials, flagged explicitly as preliminary and subject to change once the actual valuation work is completed post-close.

A fairness opinion is a formal analysis, typically delivered by an investment bank, stating whether the financial terms of a proposed transaction are fair, from a financial point of view, to a specific party (usually the target's shareholders). It's grounded in the same valuation methodologies covered elsewhere in this curriculum, comps, precedents, DCF, synthesized into a professional opinion that a board can point to as independent support for its decision.

Boards typically obtain a fairness opinion specifically to help satisfy their fiduciary duty to shareholders, demonstrating that the board undertook a rigorous, independent process before approving a transaction, rather than relying solely on management's or an interested party's own numbers.

Because the bank delivering a fairness opinion is often also advising on and earning a success fee from the same transaction, there's an inherent structural conflict: the bank has an incentive to see the deal close. Firms manage this in a few ways, some clients retain a separate, independent bank solely to deliver the fairness opinion, distinct from the deal's lead advisor, and banks maintain internal policies and disclosure practices around these conflicts.

This conflict is a frequent, direct interview question ('why might a fairness opinion not be fully independent?'), and a strong answer names the fee structure explicitly rather than dancing around it, showing an understanding of the industry's real incentive structures, not just its formal processes.

Beyond a fairness opinion, boards facing an unsolicited or contested bid have several defensive tools available: a 'poison pill' (a shareholder rights plan that makes a hostile acquisition prohibitively dilutive without board approval), a staggered board (making it harder for an acquirer to quickly replace directors), or seeking a competing 'white knight' bidder to create an auction dynamic that improves terms for shareholders. These tools are generally used to ensure the board has leverage to negotiate the best available outcome, not simply to block a deal outright, since directors still owe shareholders a fiduciary duty to maximize value in a sale process.

Understanding these defenses, and the fiduciary logic underneath them, rounds out the fairness opinion topic by connecting it to the broader legal and governance context a banker needs to be conversant in when advising a board through a contested situation.